Revolution Medicines
UnverifiedManufacturerRedwood City, CAFounded 2014Nasdaq: RVMD
Overview
Revolution Medicines is a Redwood City, California oncology company developing RAS(ON) inhibitors for RAS-addicted cancers. On August 26, 2026 the FDA approved RASONQUE (daraxonrasib) for adults with previously treated metastatic pancreatic adenocarcinoma, and the company says it is now available in the United States. Its other RAS(ON) inhibitors, including zoldonrasib, remain investigational.
Hiring snapshot
Hiring by specialty
Open roles
Newest first, from Revolution Medicines’s careers page.
- Vice President, Portfolio Sales and Field TeamRemote10d ago$294k–$367k
- Senior Oncology Account Manager, Washington DCRemote10d ago$150k–$230k
- Senior Oncology Account Manager, TampaRemote · Tampa, Florida10d ago$150k–$230k
- Senior Oncology Account Manager, SeattleRemote · Seattle, Washington10d ago$150k–$230k
- Senior Oncology Account Manager, San JoseRemote · San Jose, California10d ago$150k–$230k
- Senior Oncology Account Manager, San FranciscoRemote · San Francisco, California10d ago$150k–$230k
Divisions
Division information is pending company verification.Once Revolution Medicines claims its page, you will see each division, who it calls on and how it pays.
Claim your pageMore from Revolution Medicines
These sections fill in when Revolution Medicines claims and verifies its page.